Upexi Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Upexi heeft een totaal eigen vermogen van $22.1M en een totale schuld van $26.7M, wat de schuld-eigenvermogensverhouding op 120.9% brengt. De totale activa en totale passiva bedragen respectievelijk $56.5M en $34.5M.

Belangrijke informatie

120.9%

Verhouding schuld/eigen vermogen

US$26.66m

Schuld

Rente dekkingsratio	n/a
Contant	US$498.29k
Aandelen	US$22.06m
Totaal verplichtingen	US$34.45m
Totaal activa	US$56.51m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $16.8M ) van 7TQ0 } dekken niet de korte termijn passiva ( $24.2M ).

Langlopende schulden: De kortetermijnactiva 7TQ0 ( $16.8M ) overtreffen de langetermijnschulden ( $10.3M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 118.6% ) 7TQ0 wordt als hoog beschouwd.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van 7TQ0 de afgelopen 5 jaar is gedaald.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 7TQ0 heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: 7TQ0 heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 16.2 % per jaar.

Upexi Balans Gezondheid

Financiële gezondheid criteriumcontroles 1/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Upexi Receives Notice from the Nasdaq Stock Market

Upexi, Inc. announced delayed 10-Q filing

Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price Requirement

Upexi, Inc. announced delayed annual 10-K filing

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. announced delayed 10-Q filing

Recent updates

Upexi Receives Notice from the Nasdaq Stock Market

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024

Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price Requirement

Upexi, Inc. announced delayed annual 10-K filing

Insufficient new directors

David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

E-Core Holdings, LLC acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc., Annual General Meeting, Jun 10, 2024

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.17 profit in 2Q 2023)

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

New major risk - Share price stability

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought €70k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven